Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03431948 · ClinicalTrials.gov registry record · Phase 1
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT03431948 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 60 participants.
The verdict
NCT03431948, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
Study to determine the best dose of stereotactic body radiation therapy (SBRT) to be administered in combination with immunotherapy drugs including urelumab, cabiralizumab and nivolumab .
Interventions
- RADIATION Stereotactic Body Radiation Therapy
- DRUG Nivolumab
- DRUG Urelumab
- DRUG Cabiralizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2022-04-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03431948
The ClinicalTrials.gov registry entry for NCT03431948 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Stereotactic Body Radiation Therapy is the first listed.
NCT03431948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03431948 about?
NCT03431948 is a clinical study titled "Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer". Study to determine the best dose of stereotactic body radiation therapy (SBRT) to be administered in combination with immunotherapy drugs including urelumab, cabiralizumab and nivolumab .
What is the current status of trial NCT03431948?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2018-03-15. Estimated completion is 2022-04-11.
What interventions are being tested in trial NCT03431948?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), Nivolumab (DRUG), Urelumab (DRUG), Cabiralizumab (DRUG).
Who is sponsoring clinical trial NCT03431948?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.